- Indegene shares debut on BSE and NSE at a premium, but witness a dip due to profit-booking.
- Experts advise conservative investors to book profits, while risk-takers can hold for long term.
- Indegene’s unique position in the life sciences industry and promising outlook make it a potential long-term investment.
Indegene shares make a strong debut on BSE and NSE, but face a dip due to profit-booking. Experts weigh in on whether to buy, sell, or hold.
Indegene Shares Debut at a Premium
Despite weakness across segments on Dalal Street, Indegene share price listed on BSE and NSE at a bumper premium. The share price on BSE was ₹659.70 per share, while on NSE, it was ₹655 apiece. However, the stock could not sustain such a high premium as profit-booking triggered soon after the share debut, touching an intraday low of ₹527.10 on NSE and ₹527.80 apiece on BSE, logging a nearly 19 percent dip against the listing price. The newly listed stock witnessed some rebound and pared some losses, with the current quote at ₹600 apiece on NSE, nearly 9 percent lower than the listing price.
Expert Opinions on Indegene Share Price
Prashanth Tapse, AVP — Research at Mehta Equities, commented on the Indegene share price listing, stating, “Considering the strong subscription demand and a healthy listing gain as per our expectations against the issue price of ₹452 per share. We believe the healthy listing is justified due to its virtual monopoly in its services tailor-made for the life sciences industry and its deep domain expertise in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics, which is benefiting its clientele base across the value chain.”
Buy, Sell, or Hold?
For the Indegene share allottees post-listing, the expert advice from Mehta Equities is clear. “Post-listing, we see the valuations are getting stretched and considering market selloff mood and other parameters, we are recommending conservative investors to book profits, while risk-taking investors can continue holding for long term.” This guidance is crucial for making informed investment decisions.
Indegene’s Unique Position in the Market
Amit Goel, Co-Founder & Chief Global Strategist at Pace 360, reassures investors about Indegene Limited’s unique position in the market. “Indegene Limited stands out as a unique player in digital-led commercialization services within the Life Science Industry, boasting a virtual monopoly that generates over 98% of its global revenue. Given the promising outlook after profit-booking, investors may consider allocating funds for medium to long-term rewards.”
Conclusion
Despite the initial dip, Indegene’s unique position in the life sciences industry and its promising outlook make it a potential long-term investment. However, conservative investors are advised to book profits considering the current market conditions.
